Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy

26 de agosto de 2026 actualizado por: Hua Huang, MD, PhD

A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)

The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:

  • Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
  • Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.

Participants will:

  • Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
  • Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
  • If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
  • If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
  • In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
  • In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
  • Complete quality of life questionnaires at predefined time points
  • Be followed up for survival, disease progression, adverse events and medical resource use outcomes

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

170

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100853
        • Chinese PLA General Hospital
        • Contacto:
      • Beijing, Beijing Municipality, Porcelana, 102206
        • Peking University International Hospital
        • Contacto:
      • Beijing, Beijing Municipality, Porcelana, 100142
        • Peking University Cancer Hospital
        • Contacto:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Porcelana, 400038
        • The First Affiliated Hospital of Army Medical University
        • Contacto:
    • Fujian
      • Zhangzhou, Fujian, Porcelana, 363000
        • Zhangzhou Affiliated hospital of Fujian Medical University
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510060
        • Sun Yat-sen University Cancer Center
        • Contacto:
      • Guangzhou, Guangdong, Porcelana, 510515
        • Nanfang Hospital, Southern Medical University
        • Contacto:
          • yanfeng hu
          • Número de teléfono: +86 020-61641888
          • Correo electrónico: banby@smu.edu.cn
      • Guangzhou, Guangdong, Porcelana, 510655
        • The Sixth Affiliated Hospital, Sun Yat-sen University
        • Contacto:
    • Hubei
      • Wuhan, Hubei, Porcelana, 430030
        • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
        • Contacto:
    • Jiangsu
      • Nanjing, Jiangsu, Porcelana, 210029
        • Jiangsu Province Hospital
        • Contacto:
          • hao xu
          • Número de teléfono: +86 025-83718836
          • Correo electrónico: hxu@njmu.edu.cn
      • Nanjing, Jiangsu, Porcelana, 210009
        • Jiangsu Cancer Hospital
        • Contacto:
      • Nanjing, Jiangsu, Porcelana, 210008
        • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
        • Contacto:
      • Nantong, Jiangsu, Porcelana, 226001
        • Nantong First People's Hospital
        • Contacto:
          • shichun feng
          • Número de teléfono: +86 0513-81111888
          • Correo electrónico: fsc2200@126.com
    • Jiangxi
      • Nanchang, Jiangxi, Porcelana, 330006
        • The First Affiliated Hospital of Nanchang University
        • Contacto:
          • zhengrong li
          • Número de teléfono: +86 0791-88692748
          • Correo electrónico: lzr13@foxmail.com
      • Nanchang, Jiangxi, Porcelana, 330006
        • The Second Affiliated Hospital of Nanchang University
        • Contacto:
      • Shangrao, Jiangxi, Porcelana, 334000
        • Shangrao People's Hospital
        • Contacto:
          • jinqiang chen
          • Número de teléfono: +86 0793-8100469
          • Correo electrónico: CJQ760624@126.com
    • Jilin
      • Changchun, Jilin, Porcelana, 130021
        • The First Hospital of Jilin University
        • Contacto:
          • quan wang
          • Número de teléfono: +86 0431-88782222
          • Correo electrónico: wquan@jlu.edu.cn
    • Liaoning
      • Dalian, Liaoning, Porcelana, 116011
        • The First Affiliated Hospital of Dalian Medical University
        • Contacto:
    • Shaanxi
      • Xi'an, Shaanxi, Porcelana, 710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Contacto:
      • Xi'an, Shaanxi, Porcelana, 710038
        • The Second Affiliated Hospital of Airforce Military Medical University
        • Contacto:
    • Shandong
      • Jinan, Shandong, Porcelana, 250021
        • Shandong Provincial Hospital
        • Contacto:
      • Jinan, Shandong, Porcelana, 250014
        • The First Affiliated Hospital of Shandong First Medical University
        • Contacto:
          • jiankang zhu
          • Número de teléfono: +86 0531-89268763
          • Correo electrónico: 249217523@qq.com
      • Qingdao, Shandong, Porcelana
        • The Affiliated Hospital of Qingdao University
        • Contacto:
          • zhaojian niu
          • Número de teléfono: +86 0532-82911847
          • Correo electrónico: niuzhj@hotmail.com
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200032
        • Fudan University Shanghai Cancer Center
        • Contacto:
        • Investigador principal:
          • Hua Huang, MD,PHD
      • Shanghai, Shanghai Municipality, Porcelana
        • Shanghai General Hospital
        • Contacto:
    • Shanxi
      • Changzhi, Shanxi, Porcelana, 046000
        • Changzhi People'S Hospital
        • Contacto:
          • liang zong
          • Número de teléfono: +86 0355-2024990
          • Correo electrónico: 250537471@qq.com
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Porcelana, 300060
        • Tianjin Medical University Cancer Institute&Hospital
        • Contacto:
          • xiangyang yu
          • Número de teléfono: +86 022-23109106
          • Correo electrónico: yxynankai@126.com
    • Xinjiang
      • Ürümqi, Xinjiang, Porcelana, 830011
        • Affiliated Cancer Hospital of Xinjiang Medical University
        • Contacto:
          • wenbin zhang
          • Número de teléfono: +86 0991-7968088
          • Correo electrónico: zwb3216@sina.com
    • Zhejiang
      • Hangzhou, Zhejiang, Porcelana, 310022
        • Zhejiang Cancer Hospital
        • Contacto:
          • panpan yu
          • Número de teléfono: +86 0571-88122222
          • Correo electrónico: yupp0571@163.com
      • Hangzhou, Zhejiang, Porcelana, 310009
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • Contacto:
          • jiaqi chen
          • Número de teléfono: +86 0571-87783777
          • Correo electrónico: 2311046@zju.edu.cn
      • Hangzhou, Zhejiang, Porcelana, 310016
        • Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
        • Contacto:
          • linghua zhu
          • Número de teléfono: +86 0571-86090073
          • Correo electrónico: 3198020@zju.edu.cn

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
  • Age ≥ 18 years and ≤ 70 years.
  • Histologically and/or cytologically confirmed gastric cancer.
  • No evidence of gastric outlet obstruction or intestinal obstruction.
  • No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
  • No prior chemotherapy, targeted therapy, or immunotherapy.
  • ECOG performance status score of 0-2.
  • Life expectancy ≥ 12 weeks.
  • Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

Exclusion Criteria:

  • Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
  • Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
  • Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
  • Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
  • Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
  • Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
  • Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
  • Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
  • Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
  • Any other condition deemed by the investigator as inappropriate for participation in this study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Surgery Group
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy. Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
Comparador activo: Standard Treatment Group
Patients do not undergo surgery. They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal. Salvage surgery is permitted if clinically indicated.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Overall Survival (OS)
Periodo de tiempo: Up to 3 years after randomization
Up to 3 years after randomization

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
Periodo de tiempo: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
Periodo de tiempo: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
Pathological Complete Response (pCR) Rate
Periodo de tiempo: At the time of radical surgery
At the time of radical surgery
R0 Resection Rate
Periodo de tiempo: At the time of radical surgery
At the time of radical surgery
Complication-Free Survival
Periodo de tiempo: Up to 3 years after randomization
Up to 3 years after randomization
Major Complication Rate
Periodo de tiempo: Within 30 days and 90 days after surgery
Within 30 days and 90 days after surgery
Progression-Free Survival (PFS) and Peritoneal PFS
Periodo de tiempo: Up to 3 years after randomization
Up to 3 years after randomization
Time to Peritoneal Re-dissemination
Periodo de tiempo: Up to 3 years after randomization
Up to 3 years after randomization
Length of Hospital Stay
Periodo de tiempo: Perioperative period
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
Perioperative period
Readmission Rate
Periodo de tiempo: Within 30 days and 90 days post-surgery
Within 30 days and 90 days post-surgery
Treatment Interruption Rate
Periodo de tiempo: Within 1-year after randomization
Within 1-year after randomization
Direct Medical Costs / Hospitalization Costs
Periodo de tiempo: Baseline through study completion, an average of 3-years post-randomization
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications. Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
Baseline through study completion, an average of 3-years post-randomization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

1 de octubre de 2031

Finalización del estudio (Estimado)

1 de octubre de 2031

Fechas de registro del estudio

Enviado por primera vez

23 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de agosto de 2026

Publicado por primera vez (Actual)

27 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

26 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual-participant-level raw data will not be shared externally. Aggregated study results will be published in peer-reviewed journals.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir